Abstract
In 2013, the Ministry of Health, Labor, and Welfare (MHLW) in Japan announced a suspension of the governmental recommendation for routine HPV vaccinations. In 2020, MHLW started individual notifications of HPV vaccine to the targeted girls. In April 2022, the governmental recommendation was restarted, and catch-up vaccinations started. We evaluated the benefits and limitations of the MHLW’s new vaccination strategies by estimating the lifetime risk for cervical cancer for each birth FY under different scenarios to suggest a measure for the vaccine suspension generation. It was revealed that catch-up immunization coverage among the unvaccinated must reach as high as 90% in FY2022, when the program begins, in order to reduce the risk of the females already over the targeted ages to the same level or lower than that of women born in FY1994-1999 who had high HPV vaccination rates. For women whose vaccination coverage waned because of their birth FYs, strong recommendations for cervical cancer screening should be implemented.
Funder
Health and Labor Science Research Grant
the Japan Agency for Medical Research and Development
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference20 articles.
1. Cervical Cancer Protection in Japan: Where Are We?
2. Notices and Administrative Communication Regarding HPV Vaccine
https://www.mhlw.go.jp/content/000875155.pdf
3. Epidemiologic and Clinical Analysis of Cervical Cancer Using Data from the Population-Based Osaka Cancer Registry
4. Notices and Administrative Communication Regarding HPV Vaccine
https://www.mhlw.go.jp/content/000915791.pdf
5. Ministry of Health, Labour and Welfare, The 23rd Welfare Science Council Vaccination and Vaccine Subcommittee Side-Reaction Study Group, 26 December 2016
https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000147016.pdf
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献